选择性血清素再吸收抑制剂对血小板功能的影响:文献综述
Antoine Mokhtarian1,2, Virginie Siguret1,2, Georges Jourdi1,2
1Université Paris Cité, INSERM, Innovative Therapies in Haemostasis.
Current opinion in hematology
|October 14, 2024
概括
选择性血红素再吸收抑制剂 (SSRI) 可能会增加出血风险,但它们对血小板功能的影响尚不清楚. 证据不一致,需要进一步的研究来澄清机制和混因素.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 流行病学研究表明,选择性血红素再吸收抑制剂 (SSRI) 会增加出血风险.
- 这种增加的出血风险背后的确切机制尚不清楚.
- 血小板功能障碍是SSRI相关出血事件的潜在贡献者.
研究的目的:
- 审查和综合有关SSRI对血小板功能的影响的当前数据.
- 评估临床实践中用于评估SSRI影响的血小板功能测试.
- 确定有关SSRI和血小板相互作用的知识差距和未来研究领域.
主要方法:
- 对SSRI对血小板功能影响的文献进行系统审查.
- 分析使用各种血小板功能测试 (例如聚合,流细胞计) 的研究.
- 评估不同研究设计和方法的证据质量和一致性.
主要成果:
- 关于SSRI对血小板聚合的影响,无论是激动剂,药物类型或研究设计,都观察到相互矛盾的结果.
- 报告使用流细胞计来评估血小板表面糖蛋白,整体激活和颗粒分泌的不一致的发现.
- 从其他血小板功能测试中获得了不一致的结果,表明SSRI诱导的血小板缺陷缺乏明确的证据.
结论:
- 关于SSRI对血小板功能的影响的证据确定性非常低.
- 不一致的发现可能是由于研究设计,患者种群,SSRI类型/剂量以及混因素的变化.
- 需要进一步的研究来阐明SSRI的内在抗血小板作用以及抑郁症控制和SERT抑制的影响.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Antidepressant Drugs: Overview
2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
928
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
928


